The introductory article by Carmeliet points out that there are many potassium channels in the heart, ineluding those that respond to metabolic signals such as a fall in ATP, an increase in sodium, or an increase in calcium or adenosine. Furthermore, there are potassium channels that respond to autonomic stimuli such as acetylcholine. Other potassium channels are voltage sensitive; for example, the delayed rectifier responds to depoIarization by opening. The transient out,yard potassium current now seems important in the repolarization process.
Lazdunski decribes progress in the molecular biology of potassium channels, especially in relation to knowledge gained from cloning. It seems that many of the various voltage-dependent potassium channels are similar in structure, although channels not dependent on voltage may differ at the molecular level, apparently belonging to a different "family."
The real advance described by Dukes and Morad in this supplement is that a novel compound, tedisamil, is highly specific ~n blocking several of the voltagedependent potassium channels, particularly the transient outward and the delayed rectifier channels. The slower the kinetics of activation of the potassium channel, the greater the block induced by tedisamil.
Two of the major properties of this drug that have potential clinical application are its prolongation of the action-potential duration and the decreased rate of firing in the sinus node.
Antiarrhythmic Class III Effect
As outlined by Walker and coworkers (Adaikan et al.), tedisamil blocks, in a fairly selective manner, the transient outward and the delayed rectifier potassium channels to produce widening of the QT interval and the action-potential duration. Antiarrhythmic activity was obtained in rats and baboons. The incidence of ventricular fibrillation induced by coronary ligation in rats was reduced in a dose-dependent manner by tedisamil. The proposal is that the class III activity inhibits reentry circuits, particularly the multiple reentry circuits necessary for ventricular fibrillation.
Antiischemic and Potential Antianginal Properties of Tedisamil
It is currently attractive to consider the antiischemic potential of compounds that selectively reduce the heart rate without negative inotropic qualities. Tedisamil falls into this category of drugs. In exercised dogs with coronmg"-artery stenosis, regional systolic myocardial shortening was diminished, whereas with tedisamil treatment regional systolic myocardial shortening was much less impaired (Raberger et al.) .
In the isolated coronary ligated rat heart, tedisamil decreased the heart rate and improved the efficiency of myocardial usage of oxygen (Duchosal and Opie). Some other potentially antianginal compounds, such as verapamil, decreased the efficiency of oxygen usage.
In patients with angina, progressive doses of tedisamil (0.1-0.3 mg/kg) caused a reduction in heart rate and a slight increase in the stroke volume, particularly the higher doses, so that the cardiac output did not fall substantially. Myocardial oxygen uptake was relatively well preserved. Nonetheless, ST-segment depression was lessened during exercise.
It seems as if the degree of heart-rate reduction with compounds such as tedisamil and alinidine is not really enough to account for the antlanginal effect. Therefore, there may be other possible mechanisms of action, for example a) inhibition of potassium currents activated during ischemia or b) altered efficiency of myocardial oxygen usage.
Clinical Potential
Naturally it is too early to do more than speculate on the possible clinical value of tedisamil. At the very least a study of this unusual drug is going to teach us much more about the function of myocardial potassium channels, because of its selective blockade of the
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Opie transient outward and delayed rectified channels. This drug is potentially antianginal, acting in a manner different from beta blockers and calcium antagonists. Tedisamil also possesses antiarrhythmic properties. Of particular note is the high degree of electrophysiological specificity, so that it exhibits class III antiarrhythmic activity in concentrations much lower than those of existing drugs.
Finally, may I sincerely thank the authors and Dr. L. Ktister and her team from Kali-Chemie, all of whom gladly cooperated with this journal in its stated aim of achieving a peer-reviewed supplement of the highest possible academic standard.
L.H. 0pie M.D. Ph.D. Chairman of Symposium
